NASDAQ:VPHM - Shire Viropharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week Range$23.13 - $50.01
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.

Receive VPHM News and Ratings via Email

Sign-up to receive the latest news and ratings for VPHM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:VPHM
CUSIP92824110
Phone+1-610-4587300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Shire Viropharma (NASDAQ:VPHM) Frequently Asked Questions

What is Shire Viropharma's stock symbol?

Shire Viropharma trades on the NASDAQ under the ticker symbol "VPHM."

Has Shire Viropharma been receiving favorable news coverage?

Media headlines about VPHM stock have been trending positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Shire Viropharma earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.

What other stocks do shareholders of Shire Viropharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire Viropharma investors own include Caterpillar (CAT), General Electric (GE), Johnson & Johnson (JNJ), Mcdonald's (MCD), TJX Companies (TJX), BioMarin Pharmaceutical (BMRN), Celgene (CELG), Costco Wholesale (COST), Gilead Sciences (GILD) and Incyte (INCY).

How do I buy shares of Shire Viropharma?

Shares of VPHM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire Viropharma's official website?

The official website for Shire Viropharma is http://www.viropharma.com.

How can I contact Shire Viropharma?

Shire Viropharma's mailing address is 730 Stockton Dr, EXTON, PA 19341-1171, United States. The biotechnology company can be reached via phone at +1-610-4587300.


MarketBeat Community Rating for Shire Viropharma (NASDAQ VPHM)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  374 (Vote Underperform)
Total Votes:  599
MarketBeat's community ratings are surveys of what our community members think about Shire Viropharma and other stocks. Vote "Outperform" if you believe VPHM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VPHM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel